EAST WINDSOR, N.J.--(BUSINESS WIRE)--Aestus Therapeutics, Inc. (Aestus) today reported positive results from a Phase II clinical study evaluating the efficacy of its novel neuropathic pain therapeutic, ATx08-001, in the treatment of post-herpetic neuralgia (PHN). Results in patients on ATx08-001 monotherapy met the study’s primary objectives of demonstrating significant analgesia in PHN neuropathic pain sufferers while showing an excellent safety profile.
